RFS improved with higher Fbln2 expression in grade 2 patients (P = 0.04, n = 1177), unstratified breast cancer patients following chemotherapy (P = 0.047, n = 1935), Her2− patients following chemotherapy (P = 0.011, n = 1555), LN-patients following chemotherapy (P = 0.047, n = 1304), ER + patients following chemotherapy (P = 0.0043, n = 1229), grade 2 patients following chemotherapy (P = 0.0076, n = 580), and grade 2 patients following hormonal therapy (P = 0.018, n = 594). This evidence concerns the gene FBLN2 and breast cancer.